

## Vyvgart® Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) - New indication

- On June 21, 2024, <u>argenx announced</u> the FDA approval of <u>Vyvgart Hytrulo</u> (<u>efgartigimod alfa/hyaluronidase-qvfc</u>), for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Vyvgart Hytrulo is also approved for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
- The approval of Vyvgart Hytrulo for the new indication was based on a two-stage study that included an open-label period to identify Vyvgart Hytrulo responders (stage A), who then entered a randomized, double-blind, placebo-controlled, withdrawal period (stage B). In stage B, a total of 221 patients were randomized to receive Vyvgart Hytrulo or placebo. The primary endpoint was the time to clinical deterioration defined as a 1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) at two consecutive visits or a > 1-point increase in aINCAT at one visit.
  - Patients who received Vyvgart Hytrulo experienced a longer time to clinical deterioration compared to patients who received placebo (hazard ratio 0.394, 95% CI: 0.253, 0.614; p < 0.0001).</li>
- The recommended dosage of Vyvgart Hytrulo is 1,008 mg/11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase) administered subcutaneously over approximately 30 to 90 seconds as once weekly injections. If a scheduled injection is missed, Vyvgart Hytrulo may be administered up to 3 days after the scheduled time point. Thereafter, resume the original dosing schedule.
  - Vyvgart Hytrulo is to be administered by a healthcare professional only.
  - Refer to the Vyvgart Hytrulo drug label for dosing for gMG.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.